Levocetirizine oral films
Levocetirizine (as levocetirizine dihydrochloride) is a third-generation non-sedative antihistamine, developed from the second-generation antihistamine cetirizine. Chemically, levocetirizine is the active enantiomer of cetirizine. It is the L-enantiomer of the cetirizine racemate.
Levocetirizine works by blocking histamine receptors. It does not prevent the actual release of histamine from mast cells, but prevents it binding to its receptors.
This in turn prevents the release of other allergy chemicals and increased blood supply to the area, and provides relief from the typical symptoms of hayfever.
The manufacturers claim it to be more effective with fewer side effects than the second-generation drugs; however, there have been no published studies supporting this assertion, although other studies have concluded it may be more effective.
Available Form:
Levocetirizine DI HCL Films
We also offer Sustained (SR) / Immediate (IR) / Timed (TR) / Controlled (CR) / Delayed Release (DR) and Enteric Coated (EC).
Therapeutical:
Antiallergic
Dosage:
Levocetirizine 2 mg
Solutions from us:
- Making process suitability for your products.
- Deciding the right kind of technology / equipments for the products.
- Process Validation & Stability.
- Documentation.
- Technology transfer of products with complete line of equipments.
- Doessair preparation.
- Validation and regulatory support.
| Levocetirizine Systematic (IUPAC) Name |
Levocetirizine Identifiers |
Levocetirizine Chemical data |
||||||||||||||||||||
| 2-(2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid |
|
|
* All transactions are carried out in conformity with patent laws applicable in the user country. Active pharmaceutical ingredients or formulations thereof will not be supplied in countries where the same is under patent protection except as and if permitted under law of the country for research and development purposes only.